Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma
Abstract
References
- Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 1985;24:293-328.
- Selvam NT, Elumalai P, Venkatakrishnan V, Damodarkumar S. Molecular markers in cancer diagnosis and management: A Review. JAppl Biol Sci 2011;5: 69-74. doi: 10.1002/iso.21787
- Hussa RO. The clinical marker hCG. New York: Praeger, 1987.doi: 10.1038/modpathol.3800086
- Berhil H, Chenna H, Nouni K, et al. Malignant mesothelioma of peritoneum: about a case with review of the literature. J Cancer Sci Ther 2012;4:235-6. doi:10.4172/1948-5956.1000147
- Rich S, Presant CA, Meyer J, Stevens SC, Carr D. Human chorionic gonadrotropin and malignant mesothelioma. Cancer 1979; 43: 1457-62.
- Okamoto H, Matsuno Y, Noguchi M, et al.Malignant pleural mesothelioma producing human chorionic gonadotropin. Am J Surg Pathol 1992;16:969-74.
- Zimmerman R L, Fogt F. The β subunit of human chorionic gonadotropin lacks specificity for malignant cells in serous effusions. Modern Pathology 2004;17:701-4. doi:10.4172/1948-5956.1000147
- Ugurman F, Gozu A, Akkalyoncu B, et al. Pleural fluid and serum β-hcg levels and pleural fluıd/serum β-hcg ratio for the discrimination of malignant and benign pleural effusions. Solunum Hastalıkları 2003;14: 186-92.doi: 10.4103/0975-8844.106192
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
-
Authors
Burcak Erkol
This is me
Fugen Aker
This is me
Zeynep Gamze Kılıcoglu
This is me
Basak Ustaalioglu
This is me
Tarık Salman
This is me
Publication Date
April 1, 2016
Submission Date
April 1, 2016
Acceptance Date
-
Published in Issue
Year 2016 Volume: 29 Number: 2